The Case For Hims & Hers: Diversification And Growth Beyond Semaglutide
Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.
Novo Nordisk Down 15% in March: Is This a Buying Opportunity?
Despite the current downward trend of NVO, it is a good stock to add to one's portfolio for long-term gains due to strong ...
Hims & Hers Has Superstar Potential, But It Will Take A Lot To Get There
Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...
Medscape9d
Conflicting Data Leave Some Doubt About OA Role for GLP-1s
Weight loss from glucagon-like peptide 1 agonists clearly alleviates knee osteoarthritis pain, but other recently published data give pause regarding possible long-term adverse effects.
Healthcare Dive1d
GLP-1s are accelerating spending growth on traditional drugs, Evernorth research finds
Spending growth for simple medications used to treat common health problems is outstripping spending growth for pricey medications used to treat complex and chronic conditions, according to a new ...
I'm falling in love with exercise and am down 2 jean sizes. How 4 months on weight loss drugs has transformed my life.
A far cry from the tortured slog of calorie restriction, the process has been energizing and joyful for McDaniels — a common refrain among people on game-changing weight loss drugs. Name: Taylor ...